Ginolis Ltd delivers a development and production solution for Point of Care diagnostic tests to a Canada based company that is operating in international markets. The tests are used for assessing cardiac risks and are already available internationally.

The Ginolis solution provides increased production capacity and improved quality control with which the customer can respond to market demands. The solution is based on the modular Ginolis Delilah system.

“This deal is a major opener for us in the Canadian and North-West Americas markets,” Matti Koivu, Vice President, Business Development of Ginolis says.

The total value of the deal is not disclosed.

More information:

Matti Koivu
Vice President, Partner
Business Development
Mobile: +358 400 544 376

About Ginolis

Ginolis Ltd applies state of the art processes and technologies used within the electronics industry for development and manufacturing of MedTech and in vitro diagnostic (IVD) disposable products. The company offers its customers contract development and manufacturing of sophisticated and cost efficient micro-fabricated components, efficient automated assembly of the final products as well as turn-key standardized, modular and space-saving automated production solutions. Ginolis holds several patents and licenses for technologies in dispensing, microfluidics, electronic valves, optics and micro fabrication. Based on these patented technologies, Ginolis is also developing proprietary products that are sold to OEM customers. Ginolis is privately-held, with company roots going back to 2010. It has its headquarters in Oulu, Finland, and a subsidiary in Uppsala, Sweden.  Further information can be found at